The Trump administration has authorized a test program allowing thousands of Medicare patients to receive free CBD products. This initiative targets older adults seeking alternatives for pain, anxiety, and insomnia. Medicare CBD program aims to gather real-world evidence on whether the nonintoxicating cannabis compound can improve quality of life and reduce overall healthcare spending for seniors.

CBD is already widely used by Medicare-age patients, with a 2024 study showing 14.3 percent of those 65+ tried it. The program mandates doctor oversight, requiring providers to screen patients and collect outcome data. Doctors front the cost—up to $500 per patient annually—and share in savings if the intervention lowers broader medical expenses.

Significant regulatory hurdles loom. A recent Congressional measure threatens to remove most CBD products from the market this November due to THC content concerns. Cornbread Hemp, contracted to supply the program, may be unable to continue as its products exceed new limits. The administration's experiment now hinges on Congressional action to resolve the impending hemp ban.